Singapore, Dec 28, 2009: Vaccines have emerged as one of the most lucrative segment in the global pharmaceutical industry. With a projected CAGR of over 13% during 2009-2012, the industry will emerge as the fastest growing therapy area. The US and Europe represent the two largest vaccine markets in the world and will continue experiencing healthy growth rate in future.

 

As per the latest report on "Global Vaccine Market Forecast to 2012", by Research and Markets, the segment of pediatric vaccines presently dominates the global vaccine market; however, adult vaccine segments will define the future growth directions. The cancer vaccine market, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers.

 

The report also says that owing to lower margins and the mature nature of these markets, the basic and enhanced pediatric markets are expected to show insignificant growth in future. On the other hand, launch of a number of new vaccines will make the addiction, cancer and proprietary pediatrics/adolescent vaccine market highly dynamic. On a whole, the global vaccine market is expected to register revenues in excess of US$ 34 Billion by 2012.

 

The analysis of the competitive landscape of the global vaccine market shows a highly concentrated structure, with the top four players accounting for around 74% of the total market in 2008.